A Phase 3 interventional study of Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution and Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution in Ocular Hypertension and Open Angle Glaucoma, sponsored by Alcon Research. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 3rd largest by enrollment, is one of 4 that started in 2025, is one of 5 in phase 3, and was the 15th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Brett King · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Center for Sight Las Vegas · Sites in United States
Ages 40+
By country, each count listing its studies:
netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2025.
This study's enrollment of 489 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 85 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 19th largest by enrollment of the 112 interventional ones that give a count, is the only one that started in 2025, is one of 43 in phase 3, and was the 126th registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
2 of the studies testing netarsudil in Glaucoma, Open-Angle that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07048886Center for Sight Las VegasRocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | 2026-12-31 |
| NCT07325240Mayo Clinic24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, from their registry updates:
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
About 470 adults with OAG or OHT will be randomly divided into 2 groups. One group will use the new Reformulated PG324 eye drops, and the other group will use the marketed PG324 eye drops. This study will be double-masked, so neither the researcher nor the participant will know which eye drop was administered. The expected individual duration of participation is approximately 3 months.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
This study's enrollment of 489 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
One drop of netarsudil 0.01%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months
Drug: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
One drop of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months
Drug: Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
Drug page: Netarsudil
Investigational ophthalmic solution
Also known as: Reformulated PG324
Drug page: Netarsudil
Commercially available ophthalmic solution
Also known as: PG324, Rocklatan®
Mean Intraocular Pressure at each timepoint post-randomization
Intraocular pressure (IOP) will be measured with a Goldmann tonometer and recorded in millimeters mercury (mmHg). IOP will be calculated as the mean of two readings or the median of three readings at each timepoint.
Time frame: Week 2, Week 6, Month 3 at 08:00, 10:00, 16:00 hours
Proportion of subjects with moderate to severe conjunctival hyperemia as assessed by biomicroscopy
The subject will undergo a slit lamp examination at all visits, except for dispensing visits. The presence of moderate to severe conjunctival hyperemia (redness) will be recorded.
Time frame: Up to Month 3/study exit
Proportion of subjects with conjunctival hyperemia adverse events
Occurrences of conjunctival hyperemia (redness) adverse events, either subject or investigator reported, will be recorded at each visit.
Time frame: Up to Month 3/study exit
Mean change from diurnally adjusted baseline IOP at each timepoint post-randomization
Intraocular pressure (IOP) will be measured with a Goldmann tonometer and recorded in millimeters mercury (mmHg). IOP will be calculated as the mean of two readings or the median of three readings at each timepoint. Change is defined as the follow-up (Week 2, Week 6, and Month 3) minus baseline (Day 1) at each timepoint.
Time frame: Baseline (Day 1), Week 2, Week 6, Month 3 at 08:00, 10:00, 16:00 hours
Percent change from diurnally adjusted baseline IOP at each timepoint post-randomization
Intraocular pressure (IOP) will be measured with a Goldmann tonometer and recorded in millimeters mercury (mmHg). IOP will be calculated as the mean of two readings or the median of three readings at each timepoint. Change is defined as the follow-up (Week 2, Week 6, and Month 3) minus baseline (Day 1) at each timepoint.
Time frame: Baseline (Day 1), Week 2, Week 6, Month 3 at 08:00, 10:00, 16:00 hours
Mean TSS-IOP scores at Month 3
The Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP) module is a 15-item questionnaire designed to assess subject satisfaction with ocular hypotensive medication(s). Subjects will respond to each item using a 5-, 6-, or 7-point Likert Scale. Individual scores will be computed by adding the scale values of items within a satisfaction category and transforming the resulting value into a score between 0 and 100. Higher scores are indicative of greater satisfaction. The questionnaire will be self-administered.
Time frame: Month 3
Mean Changes in TSS-IOP scores from Screening to Month 3
The Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP) module is a 15-item questionnaire designed to assess subject satisfaction with ocular hypotensive medication(s). Subjects will respond to each item using a 5-, 6-, or 7-point Likert Scale. Individual scores will be computed by adding the scale values of items within a satisfaction category and transforming the resulting value into a score between 0 and 100. Higher scores are indicative of greater satisfaction. The questionnaire will be self-administered.
Time frame: Month 3
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Apr 2026, 7 months.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 7 months is below that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil